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LAY ABSTRACT
The context and environment in which treatment is ad-
ministered is highly relevant. Context variables are per-
ceived and interpreted by patients and can generate po-
sitive or negative expectations. Such expectations may 
influence the therapeutic outcome. This study assessed 
whether a contextual element, such as the external ap-
pearance of a shock wave device, influenced clinical out-
comes in patients with chronic plantar fasciitis. Three 
shock wave devices were compared: a standard device; 
a sophisticated device; and an austere device. The only 
difference between the devices was their external ap-
pearance. The shockwaves emitted by the 3 devices 
were identical. No differences were found between the 
3 devices for any of the variables assessed. Health pro-
fessionals and future research into the therapeutic en-
counter context should focus more on patient–therapist 
interactions than on the appearance of devices.
Objective: To determine whether the appearance of 
a radial extracorporeal shock wave device affects 
clinical outcomes in chronic plantar fasciitis. 
Study design: Randomized controlled parallel asses-
sor-blinded clinical trial. 
Material and methods: A total of 135 patients were 
assigned to 3 groups: group I, standard radial ex-
tracorporeal shock wave device; group II, standard 
radial extracorporeal shock wave device modified 
to give a more sophisticated appearance; group III, 
standard radial extracorporeal shock wave device 
modified to give a more austere appearance. The 
radial extracorporeal shock waves emitted by the 3 
devices were identical. Primary outcome was foot 
function, measured with the Foot Function Index. 
Secondary outcomes were pain at different times, 
measured with a visual analogue scale, and plantar 
fascia thickness, measured with ultrasound. 
Results: All variables decreased significantly from 
baseline assessment, in all 3 groups and at all time-
points: 1, 2, 4 and 14 months after the last session 
(p < 0.001). There were no significant differences 
between groups for any of the variables assessed. 
Conclusion: Device appearance had no statistically 
significant influence on clinical outcomes in patients 
with chronic plantar fasciitis treated with radial ex-
tracorporeal shock wave therapy.
Key words: placebo effect; nocebo effect; plantar fasciitis; 
shock wave, therapeutic context.
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Plantar fasciitis is the most common cause of inferior heel pain. Typical symptoms include pain with the 
first weight-bearing step in the morning. Diagnosis of 
plantar fasciitis can be made clinically (1). The inci-
dence and prevalence of the condition are not fully 
known; however, it is estimated that, in the general 
population, 1 in 10 people will experience plantar 
fasciitis at least once in their life (2).
Although the suffix “-itis” implies an inflammatory 
condition, mounting evidence indicates that this foot 
disorder is associated with degenerative changes and 
should be appropriately classified as a “fasciosis” or 
“fasciopathy” (3).
The causes of plantar fasciitis are multifactorial. It 
responds well to multiple conservative therapies. The 
prognosis is favourable, with resolution of symptoms 
in approximately 80% of cases (4). However, there is 
no evidence-based consensus on the most effective 
treatment. Systematic reviews have shown radial 
extracorporeal shock waves (rESW) to be effective 
and safe for the treatment of chronic plantar fasciitis 
(5–7). The biological effects of rESW are tissue rege-
neration, angiogenesis and analgesia (8, 9), produced 
by a mechanotransduction mechanism by which cells 
recognize and respond to mechanical stimulation (10).
There are many variables, including the placebo 
effect, which can explain the clinical improvement 
experienced by patients when they receive a phar-
macological treatment or physical treatment, such 
as rESW (11). The placebo and nocebo responses 
refer to changes in patients’ symptoms attributable 
to their participation in a therapeutic encounter and 
its rituals, symbols and interactions (12). However, 
other elements, such as patient–therapist relationship, 
psychosocial factors, and patients’ hopes, beliefs and 
fears, must also be considered (13, 14). 
The context and environment in which treatment is 
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perceived and interpreted by patients and can generate 
positive or negative expectations (15). A placebo re-
sponse occurs when a medical treatment and its context 
trigger specific expectations about a positive thera-
peutic outcome. Pre-existing optimistic expectations 
can amplify the positive effects of treatments (placebo 
effects), but negative expectations can also worsen 
treatment in the form of side-effects or a decrease in 
treatment-typical improvements (nocebo effects) (16).
Studies have shown that modifying the shape, colour 
or price of a placebo drug can produce different pla-
cebo responses (17, 18), yet there are few studies that 
explore and identify the contextual elements involved 
in placebo and nocebo effects; this is highly relevant, 
since the therapeutic effect of many treatments is inse-
parable from the context in which they are administered. 
However, there are other phenomena that can explain 
patients’ clinical improvement, such as the Hawthorne 
effect, natural fluctuations in diseases, and regression to 
the mean (19–21). The placebo effect can be overesti-
mated if these are not taken into account (22). 
This randomized controlled trial (RCT) aimed to as-
sess whether a contextual element, such as the external 
appearance of the rESW device, would influence clini-
cal outcomes in patients with chronic plantar fasciitis.
METHODS 
Study design
This randomized controlled parallel assessor-blinded clinical 
trial was conducted in a private rehabilitation and physioth-
erapy centre, “Salut i Esport”, in Santa Perpètua de Mogoda, 
Barcelona province, Spain. Patients were recruited from this 
centre and other private centres (n = 122) and from public cen-
tres (n = 13). A total of 135 patients were enrolled in the study 
during 2014–15.
Study participants
Patients were referred to the lead investigator and considered for 
participation in the study according to the inclusion and exclu-
sion criteria summarized in Table I. A total of 135 participants 
were recruited and 128 completed the study (Fig. 1).
After providing written informed consent, patients with 
chronic plantar fasciitis (more than 6 months’ duration) were 
randomly assigned to the following 3 groups:
• Group I: standard device: therapy applied with a standard 
rESW device (n = 45).
• Group II: sophisticated device: therapy applied with a modi-
fied standard rESW device designed to give a more attractive, 
high-tech appearance, with a larger external component 
(n = 45).
• Group III: austere device: therapy applied with a modified 
standard rESW device designed to give a more austere, 
unattractive, low-tech appearance, with a smaller external 
component (n = 45).
Three Swiss Doloclast rESW devices (EMS Electro Medical 
Systems, Nyon, Switzerland), which comply with all of the 
European safety regulations for health equipment (Registra-
tion: EN-60601-1, Class I. Type BF IP40. 93/42 EEC) were 
used. Two of the 3 devices (corresponding to groups II and III), 
which were initially standard, were modified to change only 
the external part of the device without affecting the safety of 
the treatment or the technical performance of the equipment. 
The same therapeutic radial extracorporeal shock waves were 
used in all cases.
The study was approved by the Ethics and Research Com-
mission of Blanquerna School of Health Science, Ramon Llull 
University (Barcelona, Spain). This study was carried out in 
Table I. Inclusion and exclusion criteria for patients with chronic 
plantar fasciitis enrolled in the present study
Inclusion criteria
Age over 18 years.
Able to understand the explanations about the potential benefits and risks 
of participating in the study.
Diagnosis of chronic plantar fasciitis. Tested by clinical examination, meeting 
at least 2 criteria:
• Pain on palpation of the proximal insertion of the plantar fascia (area of  
the medial tuberosity of the calcaneus).
• Pain with the first weight-bearing step in the morning and/or after a 
period of time sitting.
Duration of symptoms equal or superior to 6 months at the time of 
enrolment.
Have received conservative therapy without success, at least 2 treatments. 
The treatments may have been performed in isolation, in combination, or 
consecutively.
Non-pharmacological treatments
• Physical therapy, such as ice, heat, iontophoresis or ultrasound.
• Physiotherapy, massage or stretching.
• Orthosis.




• Topical application of analgesic or anti-inflammatory gels.
• Analgesics or oral anti-inflammatories.
• Local anaesthetic injection.
• Local corticosteroid injection.
Minimum period of time after receiving other treatments:
• 6 weeks from the last cortisone injection.
• 4 weeks from the last iontophoresis session.
Exclusion criteria
Neurological or vascular insufficiency in the painful heel.
Any inflammation at the level of the ankle.
History of rheumatic disease, collagenosis or metabolic diseases.
History of hypo- or hyperthyroidism.
Malignant disease with or without metastases.
Paget’s disease or calcaneal fat-pad atrophy.
Osteomyelitis (acute, subacute or chronic).
History of calcaneus fracture.
Patients on immunosuppressive therapy.
Patients on corticosteroid treatment longer than 3 months.
Patients with diabetes mellitus or cardiac or respiratory disease. 
Patients on anticoagulant drugs. 
Previous surgery on the painful heel.
Previous treatments with shock wave devices.
Significant abnormalities in liver function.
Pregnancy.
Infection in the treated area.
History or documented evidence of sciatica, peripheral neuropathy, such as 
nerve compression or tarsal tunnel syndrome.
History or documented evidence of systemic inflammatory disease, such 
as rheumatoid arthritis, ankylosing spondylitis, aseptic bone necrosis, or 
Reiter’s syndrome.
History or documented proof of labour compensation or litigation for medical 
conditions.
Patients who, in the opinion of the researcher, may be inappropriate for 
inclusion in the study or would not comply with the study requirements. 
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accordance with the World Medical Association 
Declaration of Helsinki (23), according to good 
clinical practice, and registered with ClinicalTri-
als.gov (identifier NCT02608723). 
Intervention
All patients followed the same schedule of visits 
in an identical setting. During the first visit, pa-
tients were given an information document about 
the study, and the lead researcher explained the 
study aims with the wording: “the 3 devices are 
effective, all 3 are good, but we want to know 
which of them is best”. Information on plantar 
fascia and gastrocnemius muscle stretching 
exercises was also provided and explained. The 
patients then underwent a baseline evaluation: 
they were asked to complete the Foot Function 
Index (FFI) questionnaire, a visual analogue 
scale (VAS) was used to assess pain, and a foot 
ultrasound was performed. Each patient was then 
taken to another room containing all 3 devices, 
where they were to be treated. The area of the tre-
atment room was 10 m2, it contained a stretcher, 
2 chairs and the 3 devices, located next to each 
other (Figs 2 and 3). A second researcher explai-
ned the treatment procedure for 1 min and how 
the 3 rESW devices worked. He fired 32 shock 
waves (4 s) into the air using each device, so that 
the patient could hear and see the operation of 
the devices. The envelope assigning the device 
to that individual was then opened. The patient 
looked at the assigned device for 1 min, and was 
then asked to remove their shoes and lie on the 
stretcher in a prone position for the first session. All patients 
received 3 sessions, 1 per week. Patient interaction with the de-
vices in the second and third session was the same as in the first 
session: the researcher explained the operation of the 3 devices 
for 1 min, then the patient observed the assigned device for 1 
min. In each session 2,500 radial extracorporeal shock waves 
were applied at a frequency of 8 Hz. The applied energy was 
adjusted to the maximum discomfort the patient could tolerate, 
resulting in an individual air pressure of between 2.0 and 4.0 
bar and, thus, a positive energy flux density of between 0.10 
and 0.18 mJ/mm2. No local anaesthesia or analgesic drugs were 
given during the sessions. The patients were followed-up at 1, 
2, 4 and 14 months after the last radial extracorporeal shock 
wave therapy (rESWT) session. 




Assigned to the 
standard device group 
(n=45) 
Total number of possible participants 
(n=234) 
Excluded (n=99) 
Did not meet eligibility criteria (n=80) 
Did not agree to participate in the study (n=19)!
Randomized (n=135) 
Assigned to the 
sophisticated device group 
(n=45) 
Assigned to the austere 







Analysed in the standard 
device group during  
(n=42) 
Analysed in the 
sophisticated device group 
(n=45) 
Analysed in the austere 
device group 
(n=41) 
Lost to follow-up in the 
standard device group 
(n=3) 
Lost to follow-up in the 
sophisticated device group 
(n=0) 
Lost to follow-up in 
austere device group 
(n=4)     
Fig. 2. The devices used in the present study: (1) sophisticated device; 
(2) austere device; (3) standard device.
Fig. 3. Close-up of the devices: (1) sophisticated device; (2) austere device; (3) standard device.
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Outcome measures
The primary outcome was foot function, measured using the 
FFI, a self-administered questionnaire that quantifies the impact 
of pathology on foot function in terms of pain, disability and 
activity restriction (24), and is one of the most-used assessment 
tools in clinical trials on plantar fasciitis treatments (25, 26). 
The index consists of 23 items that assess foot function on a 
continuous scale of 100 points, where a lower score indicates 
better function. This variable was assessed at baseline and at 
4 follow-up sessions: at 1, 2, 4 and 14 months after the last 
rESWT session.
Secondary variables included: (i) pain assessment for “pain 
with the first weight-bearing step in the morning” and “pain 
during the day”, measured with a 10-point VAS at baseline and 
at 4 follow-ups: at 1, 2, 4 and 14 months after the last rESWT 
session; (ii) plantar fascia thickness of the affected foot, mea-
sured using ultrasound (Echo Blaster EXT-128) at baseline and 
at 2 time-points: 4 and 14 months after the last rESWT session. 
Complications, adverse effects during and after treatment were 
recorded. Information was also collected on discomfort during 
the application of rESWT (using a VAS scale).
Baseline patient data collected included age, sex, body mass 
index (BMI) (kg/m2), duration of symptoms (months), time 
spent standing per day (h), exercise level (1, no activity; 2, less 
than 5 h a week; 3, between 5 and 10 h a week; 4, more than 10 
h a week), and level of education (1, no education; 2, compul-
sory education (primary and secondary school); 3, high-school 
studies or vocational training; and 4, university-level education).
Randomization and blinding
Randomization was performed through a specific syntax for this 
study, in IBM-SPSS language (V22), in blocks and perfectly 
balanced by a statistician from the Ibero-American Cochrane 
Centre, Clinical Epidemiology and Public Health Service of the 
Hospital de la Santa Creu i Sant Pau. The randomization num-
bers were placed in sealed opaque envelopes, thus concealing 
allocation from both the patients and the therapist until treatment 
started. The envelopes were sequentially ordered from 1 to 135 
and stored in a locked cabinet. Both the lead researcher (who 
assessed patients for eligibility) and the researcher responsible 
for delivering the treatment had no access to the content of the 
envelopes, ensuring the concealment of assignments. The pa-
tients and the therapist were not blinded to the treatment due to 
the nature of the study, as they knew which of the 3 devices was 
being applied, but the evaluator and data analyst were blinded. 
Statistical analysis
Descriptive values are expressed as means and standard devia-
tions (SD) for quantitative variables, and relative frequency for 
categorical variables.
As the main study analysis, a 2-way analysis of variance 
(ANOVA) was performed, with groups (3 levels: (groups I, II 
and III)) and time (5 levels (baseline and follow-ups) of repeated 
measures) as independent variables, and clinical variables (foot 
functionality, morning pain, pain during the day, and plantar 
fascia thickness) as dependent variables.
For secondary analysis with categorical variables a χ2 test 
was performed. Finally, in the case of quantitative variables, 
the inferential analysis was carried out with analysis of va-
riance (ANOVA); the Kruskal–Wallis test was performed as 
a non-parametric test alternative to ANOVA (failure to meet 
assumptions or for ordinal variables).
The sample size was calculated using GRANMO Software 
(Version 7.12, IMIM-Hospital del Mar, Barcelona, Spain), with 
the assumption that an ANOVA would be performed among the 
3 groups and 5 time-points. Accepting a p-value below 0.05 and 
a statistical power (beta-1 risk) above 0.8 in a bilateral contrast, 
45 patients were required in each group to detect a minimum 
difference of 15 points between 2 groups, assuming that there 
were 3 groups and a standard deviation (SD) of 20. A maximum 
rate of 15% loss to follow-up was estimated.
Calculations were performed using IBM-SPSS (Version 22, 
IBM, Armonk, NY, USA).
RESULTS
Baseline patient data
A total of 135 patients participated in the study; 45 in 
each group. Mean age was 49 years, and 48% of the 
patients were women. Mean duration of symptoms was 
14 months. Table II shows the baseline patient data. 
Table II. Baseline data
Group I: standard device 
(n = 45)
Mean (SD)
Group II: sophisticated device 
(n = 45)
Mean (SD)
Group III: austere 
device (n = 45)
Mean (SD) p-value
Age, years 48.27 (9.96) 52.51 (12.28) 49.31 (11.14) 0.054*
Body mass index, kg/m2 27.61 (3.31) 27.66 (3.72) 28.35 (5.25) 0.642
Duration of symptoms, months 13.27 (9.26) 14.98 (12.72) 13.53 (9.09) 0.708
Hours spent standing per day 7.67 (3.53) 8.80 (3.67) 8.33 (4.09) 0.362
Sex, n (%)
  Female 33.3 60 51.1 0.036*
  Male 66.7 40 48.9
Exercise, n (%)
  No activity 44.4 44.4 57.8 0.407
  Low activity 35.6 42.2 28.9
  Moderate activity 15.6 13.3 8.6
  Intense activity 4.4 0 4.4
Educational level, n (%) 0.166
  No education 2.2 8.9 6.7
  Compulsory education 35.6 44.4 31.1
  High-school education or vocational training 33.3 28.9 33.3
  University education 28.9 17.8 28.9
*At baseline, significant differences were observed between groups for the distribution of the variable sex (p = 0.036), and for the variable age, the difference 
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In this clinical trial there was no loss to follow-up 
after the first, second and fourth months after inter-
vention, but there were 7 patients lost to follow-up 
after the 14th month due to lack of interest or time 
constraints; hence 128 patients completed the study 
and were analysed.
Influence of device appearance on foot function 
The data showed no significant interaction effect be-
tween treatment group and time for the FFI variable 
(F (6.857, 428.554)= 0.064; p = 0.863). However, there was a 
significant time effect (F (3.428, 428.554)=209.31; p < 0.001); 
that is, a significant decrease from baseline in all 3 
groups. No significant differences were found among 
groups (main effect) (F (2,125)=0.196; p = 0.611). (Fig. 4).
Influence of device appearance on pain with the first 
weight-bearing step in the morning
For the VAS variable there was no significant inte-
raction effect between group and time (p = 0.910). 
There was a significant time effect (p < 0.001), with a 
significant decrease from baseline assessment in all 3 
groups. No significant differences were found among 
groups (main effect) (p = 0.623) (Fig. 5).
Influence of device appearance on pain during the day
For the VAS variable there was no significant inte-
raction effect between group and time (p = 0.853). 
There was a significant time effect (p < 0.001), with a 
significant decrease from baseline assessment in all 3 
groups. No significant differences were found among 
groups (main effect) (p = 0.599) (Fig. 6).
Influence of device appearance on plantar fascia 
thickness 
There was no statistically significant interaction ef-
fect between group and time (p = 0.402) for plantar 
fascia thickness. There was a significant time effect 
(p < 0.001); i.e. a significant decrease from baseline 
assessment in all 3 groups. There were no significant 
differences between groups (main effect) (p = 0.800) 
(Fig. 7). 
Influence of device appearance on adverse effects 
No serious side-effects or complications were observed 
in any group. Adverse effects were increased heel pain 
in 19 patients and headache in 9 patients. These effects 
appeared after application of rESWT and resolved 
completely in 4 days without requiring treatment. No 
other adverse events were observed and no significant 
differences were found among groups (p = 0.473). 
Regarding the discomfort perceived by patients during 
the application of rESWT, there were no significant 
differences between groups (p = 0.660).
DISCUSSION
Broadly, the placebo and nocebo effects consist of an 
improvement or worsening of symptoms that is attribu-
table to the context of the patient-therapist relationship. 
Fig. 4. Foot Function Index (FFI) over time, by device group. Time 
factor p < 0.001; device factor p=0.863; device-time interaction factor 
p = 0.611. **The whole analysis was adjusted, correcting for age and 
sex of the patients, by means of a co-variance analysis (ANCOVA). 
























Group I- Standard device Group II- Sophisticated Device Group III- Austere device 
Fig. 5. Visual analogue scale (VAS) assessment of pain with the first 
weight-bearing step in the morning, over time and by device group. 
Time factor p < 0.001; device factor p = 0.910; device–time interaction 
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Therapeutic context includes a multitude of signals 
inherent to any intervention, which are perceived and 
interpreted by patients and generate positive or nega-
tive expectations (12). Placebo and nocebo effects can 
be generated from expectations (27–29); therefore it is 
important to assess contextual factors that can generate 
expectations and their impact on clinical outcomes. 
This RCT was designed to evaluate the influence of 
the appearance of a physical agent; in this case a rESW 
device, on clinical outcomes in plantar fasciitis.
It was found that, in the treatment of chronic plantar 
fasciitis with rESW, the appearance of the device did 
not significantly affect the clinical results. None of 
the 5 clinical variables analysed (foot function, pain 
with the first weight-bearing step in the morning, pain 
during the day, plantar fascia thickness, and adverse 
effects) showed statistically significant differences bet-
ween the 3 groups: patients had similar results regard-
less of the treatment device (standard, sophisticated, 
or austere device). Furthermore, all patients improved 
significantly over time in relation to the baseline assess-
ment. The improvement was observed equally in all 3 
groups and at all assessment time-points: 1, 2, 4 and 14 
months after the last rESWT session, with no statisti-
cally significant differences among groups over time. 
That is, the clinical outcomes were independent of the 
device used. Although the appearance of the device 
neither improved nor worsened treatment outcomes, as 
shown in this study, small differences were observed 
between the austere group and the other groups. The 
austere group obtained, in most evaluations, the worst 
clinical outcomes.
Despite an extensive neuroscience base that supports 
the placebo effect, there is a lack of clinical research 
that explores, in a healthcare setting, the context and 
placebo responses that accompany the overall thera-
peutic intervention. Most existing knowledge about the 
placebo effect has come from studies in basic science 
and clinical trials that are far removed from usual clini-
cal practice. However, it has been found that placebo 
responses are greater under these conditions than in 
clinical trials conducted in real healthcare settings (21).
Few clinical trials have analysed treatment context 
factors, such as the appearance of a physical agent 
and its possible influence on patient recovery, making 
it difficult to compare the results of the current study 
with those obtained in similar studies. In a study con-
ducted by Dawes et al. (30), 2 identical hearing aids 
were compared: 1 described as “new” and the other as 
“conventional”. Approximately 75% of the participants 
preferred the new device and reported that the hearing 
quality it provided was superior to the conventional 
one (30). Another clinical trial, with real patients, 
investigated the influence of different verbal infor-
mation combined with a real analgesic drug (31) and 
reported similar results to the present study, showing no 
differences in pain reduction. Furthermore, in a cros-
sover clinical trial, it was shown that the same person 
may respond differently to different types of placebo 
(placebo tablet or sham acupuncture). The response 
to placebo is a complex phenomenon that has many 
variables and goes beyond patient characteristics. This 
could explain the difficulty of detecting a pattern for 
people “responding to placebo” (32, 33).
The magnitude of the placebo effect depends on 
numerous design factors. A 2015 meta-analysis found 
that the type of active drug (opioid or non-steroidal 
anti-inflammatory drug (NSAID)), the scheduled 
follow-up visits (number of planned face-to-face vi-
sits), and randomization ratio (probability of receiving 
a placebo treatment, 1:4 or 1:1) were predictive of the 
magnitude of the placebo response, thereby supporting 
the expectancy hypothesis. Exploratory models sho-
Fig. 6. Visual analogue scale (VAS) assessment of pain during the day, 
over time and by device group. Time factor p < 0.001; device factor 


























Group I- Standard device Group II- Sophisticated Device Group III- Austere device 
Fig. 7. Fascia thickness over time and by device group. Time factor 
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was a group without treatment. Another limitation of 
this study was the presence of the 3 devices in the same 
room, since in a real healthcare setting only a single 
device would be available. This could increase patients’ 
expectations and thus generate placebo or nocebo re-
sponses. This aspect might have been relevant for the 
external validity of the study, if differences had been 
found between the groups.
The current study may have some practical conse-
quences. The results could encourage the industry to 
manufacture rESW devices with a more austere design, 
which would allow lower production costs. Therefore, 
equipment and treatment sessions would be cheaper, 
potentially increasing the number of patients who could 
access this therapy. 
Creative experimental efforts are needed to rigo-
rously assess the clinical significance of placebo and 
nocebo effects and investigate the individual elements 
that may contribute to a therapeutic benefit. Future 
research should place more emphasis on patient–thera-
pist interactions rather than the diagnostic and thera-
peutic tools used. The placebo effect must be isolated 
from other phenomena present in clinical trials, such as 
the Hawthorne effect, natural fluctuations in diseases, 
and regression to the mean (20–22). These phenomena 
can cause confusion and lead to clinical improvements 
being wrongly attributed to a placebo effect.
Conclusion
In patients with chronic plantar fasciitis treated with 
rESW therapy, the appearance of the device did not 
influence clinical outcomes: function, pain with the 
first weight-bearing step in the morning, pain during 
the day, fascia thickness, and adverse effects. As device 
appearance did not affect treatment outcomes, it should 
not currently be considered as one of the contextual 
elements that generate placebo and nocebo responses. 
Further research is needed to identify the contextual va-
riables, including patient-therapist interactions, which 
influence such responses. 
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